Key Takeaways
AbbVie (
ABBV
) has agreed to license a weight-loss drug currently in development from Danish biotech firm Gubra for up to about $2.2 billion, signaling its entry in the obesity treatment market.
Abbvie will pay $350 million up front and as much as $1.875 billion during development and commercialization of the drug, GUB014295, which is currently in a Phase 1
clinical trial
.
The drug could give AbbVie an answer to weight-loss treatments from Eli Lilly (
LLY
) and Novo Nordisk (
NVO
), which have
dominated a market
that serves the 40% of U.S. adults with obesity. Goldman Sachs analysts estimated last year that the market for weight-loss drugs could reach $130 billion by 2030.
Gubra’s drug, also known as GUBamy, acts as an analog of the hormone amylin, which has been identified as a potential therapeutic target for treating obesity, the company said. That’s different from drugs such as
Novo Nordisk’s Ozempic
or
Lilly’s Zepbound
, which involve the hormone GLP-1.
Shares of AbbVie gained more than 1% intraday Monday and are up nearly 20% since the start of the year.
Read the original article on
Investopedia
